TP53 and hepatocellular carcinoma: Before fully elucidating the interaction between these drugs and molecules, we cannot assume that the additive anti-HCC effect of magnolol/MM1 and sorafenib is entirely due to the activation of the p21 and p53 tumor suppression pathways.